Biontech aims to expand | News

While Biontech chief Ugur Sahin assumes the adapted Covid 19 vaccine could be approved by Western authorities by fall, he is silent on virtual AGM for approval in China.

According to Sahin, the US Food and Drug Administration (FDA) is planning a meeting in late June to determine what the agency expects of vaccines adapted to the omicron variant. Sahin also expects the European Medicines Agency (EMA) to take such a step. Depending on the authorities’ decision, an adapted vaccine could be approved in August, September or fall, Sahin said.

Biontech and its American partner Pfizer are working on a vaccine adapted to the omicron variant. In January, they began clinical trials. Clinical trial results are expected in the coming weeks. Based on clinical data, the approving authorities would define a further regulatory procedure that would be necessary for the possible approval of an adapted vaccine.

Register now and buy a Biontech share

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

The company has not said when the vaccine will be approved in China. He confirmed that the decision is in the hands of the Chinese authorities with whom Biontech is in talks.

The Mainz vaccine is one of the most used vaccines in the world against Covid-19. However, it is still not on the market in China, although Biontech already in spring 2020 concluded a license agreement with the Chinese company Fosun Pharma for the development and sale of a vaccine in China, Hong Kong, Macau and Taiwan. Until now, only vaccines developed and manufactured in China – primarily Sinovac and Sinopharm – have been used in the People’s Republic of China.

Biontech makes it available without momentum

Over the past few months, Biontech stocks have felt a calming effect from the corona crisis. Despite China’s fantasies and new trading opportunities, the stock’s outlook remains limited, as recent stock market reactions have shown. The stocks have been swinging sideways for months from around $ 120 to almost $ 190, and the MACD (Momentum) is also unable to provide any impetus.

Biontech’s success can be attributed, among others, to purchase of shares participate. Brave investors can get leverage with Buy CFDs get involved.

It’s that simple to buy stocks on eToro.

The eToro platform offers traders from all over the world the unique opportunity to add shares to their portfolio. From the beginning of 2018, each BUY non-leveraged order causes eToro to buy the underlying asset; it will then be held on behalf of the client. This also applies to cases where you invest in CopyPortfolio or copy an investor: if the copied investor buys shares, you automatically own a portion of his share portfolio.

Trade stocks with eToro, here are the advantages:

  • trust Your shares will be held in your name in an EU regulated company.
  • insurance Your deposit and related assets are insured under CySEC’s Terms of Use.
  • dividends If the company pays dividends, investors will be allocated an appropriate dividend.
  • No care fees Buying stocks on eToro means you no Pay storage and ordering fees and commissions. There is a bid-ask spread when buying and selling stocks.
  • Easy-to-use Your warehouse is always available online and via the app.
  • diversification Create a portfolio of stocks, cryptocurrencies, commodities, and more.

Register now and buy stocks

About eToro:

For over a decade, eToro has been at the forefront of the global fintech revolution. It is the world’s leading social trading network, with millions of registered users and a host of innovative trading and investing tools. Since the beginning of 2018, eToro allows you to buy and sell stocks.

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

advertisement

Leave a Comment